Following is a cumulative list of Hoosier Cancer Research Network publications in bladder cancer.

Manuscripts and Journal Articles

• E Miller, T Rose, B Maughan, M Milowsky, M Bilen, B Carthon, X Gao, S Rapisuwon, Q Zhao, M Yu, N Agarwal, M Galsky. Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade HCRN-GU17-294. DOI: 10.1002/cncr.35179 Cancer. 2024 January 5. See Abstract. 
• M Galsky, S Daneshmand, S Izadmehr, E Gonzalez-Kozlova, K Chan, S Lewis, B El Achkar, T Dorff, J Paul Cetnar, B Neil, A D’Souza, R Mamtani, C Kyriakopoulos, T Jun, M Gogerly-Moragoda, R Brody, H Xie, K Nie, G Kelly, A Horwitz, Y Kinoshita, E Ellis, Y Nose, G Ioannou, R Cabal, G Kenneth Haines, L Wang, K Mouw, R Samstein, R Mehrazin, N Bhardwaj, M Yu, Q Zhao, S Kim-Schulze, R Sebra, J Zhu, S Gnjatic, J Sfakianos, S K. Pal. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial HCRN-GU16-257. DOI: 10.1038/s41591-023-02568-1 Nature Communications. 2023 October 2. See Abstract. 
• D Doroshow, P O’Donnell, J Hoffman-Censits, S Gupta, U Vaishampayan, E Heath, P Garcia, Q Zhao, M Yu, M Milowsky, M Galsky. Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations: HCRN-GU15-262. DOI: 10.1200/PO.23.00095 JCO Precision Oncology. 2023 July 6. See abstract.
• MD Galsky, A Mortazavi, MI Milowsky, S George, S Gupta, MT Fleming, LH Dang, DM Geynisman, R Walling, RS Alter, M Kassar, J Wang, S Gupta, N Davis, J Picus, G Philips, DI Quinn, GK Haines III, NM Hahn, Q Zhao, M Yu, SK Pal. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: HCRN GU14-182. DOI: 10.1200/JCO.19.03091 Journal of Clinical Oncology. See abstract. PMID: 32271672
• NM Hahn, TJ Bivalacqua, AE Ross, GJ Netto, A Baras, JC Park, C Chapman, TA Masterson, MO Koch, R Bihrle, RS Foster, TA Gardner, L Cheng, DR Jones, K McElyea, GE Sandusky, T Breen, Z Liu, C Albany, ML Moore, RL Loman, A Reed, SA Turner, FB De Abreu, T Gallagher, GJ Tsongalis, ER Plimack, RE Greenberg, DM Geynisman. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. Clin Cancer Res. 2017 Jun 15;23(12):3003-3011. doi: 10.1158/1078-0432.CCR-16-2267. Epub 2016 Dec 8. PMID: 27932416
• NM Hahn, BS Knudsen, S Daneshmand, MO Koch, R Bihrle, RS Foster, TA Gardner, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CL Corless, AS Alva, SS Shen, F Huang, A Gertych, GE Gallick, J Mallick, C Ryan, MD Galsky, SP Lerner, EM Posadas, G Sonpavde. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Hoosier Cancer Research Network GU07-122. Urol Oncol 2015 Sep 8. pii S1078-1439(15)00402-0. doi: 10.1016/j.urolonc.2015.08.005. [Epub ahead of print] PMID: 26362343
• NM Hahn, WM Stadler, RT Zon, D Waterhouse, J Picus, S Nattam, CS Johnson, SM Perkins, MJ Waddell, CJ Sweeney. Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU04-75. J Clin Oncol. 2011 Mar 21. [Epub ahead of print] PMID: 21422406
• CJ Sweeney, BJ Roth, FF Kabbinavar, DJ Vaughn, M Arning, RE Curiel, CK Obasaju, Y Wang, SJ Nichol, DS Kaufman. Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium: Hoosier Oncology Group GU00-13. J Clin Oncol. 2006 Jul 20;24(21):3451-7 PMID: 16849761
• J Li, B Juliar, C Yiannoutsos, R Ansari, E Fox, MJ Fisch, LH Einhorn, CJ Sweeney. Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study GU98-2. J Clin Oncol 2005;23 1185-1191 PMID: 15718315

Abstracts, Posters, and Presentations

• MD Galsky, S Daneshmand, KG Chan, TB Dorff, JP Cetnar, B O’Neil, A D’souza, R Mamtani, C Kyriakopoulos, P Garcia, S Izadmehr, M Yu, Q Zhao, R Mehrazin, SC Lewis, J Sfakianos, SK Pal. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU16-257. Presented as an oral abstract at the ASCO 2021 Annual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 4503) See abstract.
• D Kilari, A Szabo, KA Bylow, RS Alter, AA Nelson, E Lemke, WA Hall, S Johnson, P Langenstroer, K Jacobsohn, NB Davis, C Fung, MI Milowsky. A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study. Presented as a Trials in Progress Poster at the ASCO 2021 Annual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr TPS4591). See abstract.
• JS Damrauer, J Klomp, W Beck, M Zhou, E Plimack, M Galsky, P Grivas, N Hahn, P O’Donnell, G Iyer, DI Quinn, KA Hoadley, WY Kim, MI Milowsky. Urothelial cancer-GENOmic analysis to improve patient outcomes and research (UC-GENOME): a bladder cancer advocacy network (BCAN) led collaborative research study: HCRN GU15-217. Presented as a poster at the American Association for Cancer Research (AACR) 2021 Annual Meeting. See abstract.
• M Milowsky, N Davis, C Fung, S Johnson, P Langenstroer, K Jacobsohn, K Bylow, D Kilari. A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE): HCRN GU18-343. Presented as a Trials in Progress E-Poster at the ESMO 2020 Virtual Congress, Sept. 17, 2020. Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274. See abstract.
• NM Hahn, MA O’Donnell, JA Efstathiou, M Zahurak, G Rosner, J Smith, MR Kates, TJ Bivalacqua, PT Tran, DY Song, AS Baras, A Matoso, W Choi, KN Smith, DM Pardoll, L Marchionni, B McGuire, B Johnson, T O’Neal, DJ McConkey, TL Rose, M Bjurlin, EA Lim, CG Drake, CB Anderson, DL Lamm, DM Geynisman, MA Hallman, EM Horwitz, E Al-Saleem, DYT Chen, A Kutikov, G Guo, TA Masterson, N Adra, HZ Kaimakliotis. Phase 1 trial of durvalumab in combination with BCG or external beam radiation in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Trial). Presented at the Society of Urologic Oncology 2020 Annual Meeting. See abstract.
• AV Balar, SA Funt, S Gupta, AZ Dudek, AR Boiles, DA Vanea, D Kilari, JE Rosenberg. Hcrn GU15-215: A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC). Presented as at ASCO Annual Meeting 2020. See abstract. 
• CJ Hoimes, N Adra, MT Fleming, HZ Kaimakliotis, J Picus, ZL Smith, R Walling, EJ Trabulsi, JH Hoffman-Censits, MO Koch, C Cary, R Abouassaly, C Eitman, P Fu, G Goolamier, AC Calaway, LE Ponsky, WK Kelly. Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188. Presented as a poster at the ASCO 2020 Annual Meeting. See abstract.
• HZ Kaimakliotis, N Adra, WK Kelly, EJ Trabulsi, RC Lauer, J Picus, ZL Smith, R Walling, TA Masterson, AC Calaway, MO Koch, E Sonderman, P Fu, G Goolamier, C Eitman, LE Ponsky, CJ Hoimes. Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188. Presented as a poster discussion at the ASCO 2020 Annual Meeting. See abstract.
• N Adra, RJ Hauke, HZ Kaimakliotis, S Gulati, N Hashemi, R Pili. Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma HCRN GU17-295. Accepted as a Trials In Progress Poster at the 2020 Genitourinary Cancers Symposium, February 14, 2020. J Clin Oncol 38, 2020 (suppl 6; abstr TPS587). See abstract.
• MD Galsky, SK Pal, A Mortazavi, MI Milowsky, S George, S Gupta, MT Fleming, LH Dang, DM Geynisman, R Walling, RS Alter, EL Robin, J Wang, S Gupta, DD Chism, J Picus, G Philips, DI Quinn, NM Hahn, M Yu. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182. Accepted as an oral abstract at the ASCO Annual Meeting, May 31 – June 4, 2019, Chicago IL. DOI: 10.1200/JCO.2019.37.15_suppl.4504 Journal of Clinical Oncology 37, no. 15_suppl (May 20 2019) 4504-4504. See abstract.
• CJ Hoimes, C Albany, J Hoffman-Censits, M Fleming, E Trabulsi, J Picus, C Cary, MO Koch, R Walling, WK Kelly, JL Godwin, M Cooney, P Fu, A Nelson, K Patel, C Eitman, T Breen, A Neal, H Kaimakliotis. A Phase 1b/2 Multicenter Study of Neoadjuvant Pembrolizumab and Chemotherapy for Locally Advanced Urothelial Cancer (NCT02365766): HCRN GU14-188. Accepted as a late-breaking abstract poster discussion at the 2018 ESMO Congress, Oct. 20, 2018, Munich, Germany. See abstract.
• TK Choueiri, NM Hahn, L Werner, MM Regan, JE Rosenberg, BOREALIS-02 Investigators. Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC) (Hoosier Cancer Research Network GU12-160). Accepted to Poster Session B at the ASCO 2017 Genitourinary Cancers Symposium, February 16-18, 2017, Orlando, Fla. J Clin Oncol 35, 2017 (suppl 6S; abstract 289). See abstract.
• CJ Hoimes, R Abouassaly, JN Saltzman, MT Fleming, JH Hoffman-Censits, T Byrd, C Eitman, M Snyder-Willis, J O’Neill, L Wood, R Elliott, MM Cooney. HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC). Accepted as a trials in progress poster session at the ASCO Annual Meeting, June 3-7, 2016, Chicago IL. J Clin Oncol 34, 2016 (suppl; abstr TPS4578). See abstract.
• NM Hahn, TJ Bivalacqua, A Ross, GJ Netto, JC Park, TA Masterson, MO Koch, R Bihrle, R Foster, TA Gardner, L Cheng, DR Jones, K McElyea, G Sandusky, Z Liu, SA Turner, GJ Tsongalis, ER Plimack, RE Greenberg, DM Geynisman. Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157. Accepted as a poster session at the ASCO Annual Meeting, June 3-7, 2016, Chicago IL. J Clin Oncol 34, 2016 (suppl; abstr 4526). See abstract.
• B Knudsen, NM Hahn, S Daneshmand, EM Posadas, S Muhanty, SP Lerner, G Sonpavde. Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC): Hoosier Oncology Group GU07-122. Accepted to the General Poster Session (Abstract #324) at the 2014 Genitourinary Cancers Symposium, January 30 – February 1, 2014, Orlando FL. J Clin Oncol 32, 2014 (suppl 4; abstr 324)
• BA Gartrell, NM Hahn, TE Hutson, G Sonpavde, RJ Hauke, A Starodub, AC Small, C-K Tsao, MD Galsky. Phase II trial of gemcitabine and cisplatin plus ipilimumab as first-line treatment for metastatic urothelial carcinoma: Hoosier Oncology Group GU10-148. Accepted as a Poster Presentation at the Trials in Progress Session at the ASCO Annual Meeting, June 1-5, 2012, Chicago, IL. J Clin Oncol 30, 2012 (suppl; abstr TPS4676). See abstract.
• N Hahn, S Daneshmand, EM Posadas, MO Koch, R Bihrle, R Foster, TA Masterson, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CW Ryan, CL Corless, MD Galsky, AS Alva, C Mitchell, SS Shen, SP Lerner, G Sonpavde. A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial. Accepted to the General Poster Session (Abstract #4586) at the ASCO Annual Meeting, June 1-5 2012, Chicago IL. J Clin Oncol 30, 2012 (suppl; abstr 4586). See abstract.
• S Lerner, NM Hahn, T Powles, TA Gardner, L Cheng, JS Green, DM Berney, D Taber, J Hudak, J Landgraf, S Shen, G Sonpavde. A Phase II Trial of Neoadjuvant Cisplatin (C), Gemcitabine (G), and Sunitinib (S) in Muscle-Invasive Urothelial Carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 Trial. Accepted as abstract at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr e15173)
• NM Hahn, WM Stadler, R Zon, DM Waterhouse, J Picus, SR Nattam, CS Johnson, SM Perkins, MJ Waddell, C Sweeney. Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). Accepted as a poster discussion at the ASCO annual meeting June 4-8, 2010, Chicago IL J Clin Oncol 28:15s, 2010 (suppl; abstr 4541)
• NM Hahn, WM Stadler, RT Zon, D Waterhouse, J Picus, S Nattam, CS Johnson, SM Perkins, CJ Sweeney. A Multicenter Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) As First-Line Chemotherapy for Metastatic Urothelial Carcinoma (UC); Hoosier Oncology Group GU04-75. Accepted as an oral presentation at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL. J Clin Oncol 27:15s, 2009 (suppl; abstr 5018)
• CJ Sweeney, BJ Roth, DS Kaufman, SJ Nicol. A Phase II Study of ALIMTA in Patients with Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium): A Hoosier Oncology Group Study GU00-13. Accepted as a poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL
• J Li, B Juliar, R Ansari, E Fox, M Fisch, L Einhorn, C Sweeney. A Phase II Study of Weekly Paclitaxel (P) and Gemcitabine (G) in Advanced Transitional Cell Carcinoma (TCC) of the Urothelium): A Hoosier Oncology Group Study GU98-2. Accepted as a poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL
• R Parameswaran, M Fisch, C Sweeney, L Einhorn. A Hoosier Oncology Group Phase II Study of Weekly Paclitaxel and Gemcitabine in Advanced Transitional Cell Carcinoma (TCC) of the Bladder: GU98-2. Accepted as a poster presentation for ASCO annual meeting May 12-15, 2001, San Francisco, CA.